[1] |
中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205. Chronic Obstructive Pulmonary Disease Group of Respiratory Branch of Chinese Medical Association, Working Committee of Chronic Obstructive Pulmonary Disease of Respiratory Physicians Branch of Chinese Medical Association. Guidelines for the diagnosis and management of chronic obstructive pulmonary disease (revised version 2021)[J]. Chin J Tuberc Respir Dis, 2021, 44(3): 170-205. DOI:10.3760/cma.j.cn112147-20210109-00031 |
|
[2] |
Chen CC, Lin CH, Hao WR, et al. Influenza vaccination and the risk of ventricular arrhythmias in patients with chronic obstructive pulmonary disease: a population-based longitudinal study[J]. Front Cardiovasc Med, 2021, 8: 731844. DOI:10.3389/fcvm.2021.731844 |
|
[3] |
中华预防医学会疫苗与免疫分会. 主要慢性病人群流感疫苗和肺炎球菌疫苗接种专家共识[J]. 中国疫苗和免疫, 2021, 27(6): 711-742. Vaccine and Immunization Branch, Chinese Preventive Medicine Association. Association expert consensus on influenza vaccination and pneumococcal vaccination for patients with certain chronic diseases[J]. Chin J Vaccin Immun, 2021, 27(6): 711-742. DOI:10.19914/j.CJVI.2021130 |
|
[4] |
周志强, 曲建卫, 咸本松, 等. 慢性阻塞性肺疾病患者接种肺炎球菌疫苗疗效的Meta分析[J]. 中华全科医学, 2018, 16(9): 1562-1565, 1574. Zhou ZQ, Qv JW, Xian BS, et al. Meta-analysis of efficacy of pneumococcal vaccination in patients with chronic obstructive pulmonary disease[J]. Chin J Gen Prac, 2018, 16(9): 1562-1565, 1574. DOI:10.16766/j.cnki.issn.1674-4152.000425 |
|
[5] |
Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD[J]. Thorax, 2006, 61(3): 189-195. DOI:10.1136/thx.2005.043323 |
|
[6] |
荣恒漠, 杨炯. 肺炎疫苗应用于支气管扩张症及慢性阻塞性肺疾病患者的效果[J]. 武汉大学学报: 医学版, 2017, 38(1): 90-95. Rong HM, Yang J. Effect of 23-valent pneumococcal polysaccharide vaccine on patients with bronchiectasis and patients with COPD[J]. Med J Wuhan Univ, 2017, 38(1): 90-95. DOI:10.14188/j.1671-8852.2017.01.022 |
|
[7] |
Ohshima N, Nagai H, Matsui H, et al. Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease[J]. Vaccine, 2014, 32(10): 1181-1186. DOI:10.1016/j.vaccine.2013.09.060 |
|
[8] |
Li Y, Ma Y, An ZJ, et al. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in patients with chronic obstructive pulmonary disease - Hebei province, China, September-December, 2019[J]. China CDC Wkly, 2021, 3(16): 331-334. DOI:10.46234/ccdcw2021.089 |
|
[9] |
温莹, 何柳, 翟屹, 等. 流行性感冒病毒裂解疫苗和23价肺炎球菌多糖疫苗改善老年人慢性阻塞性肺疾病的社区干预试验[J]. 中华流行病学杂志, 2018, 39(6): 792-798. Wen Y, He L, Zhai Y, et al. Effect of influenza and 23-valent pneumococcal polysaccharide vaccinations on elderly with chronic obstructive pulmonary diseases: a community-based intervention study[J]. Chin J Epidemiol, 2018, 39(6): 792-798. DOI:10.3760/cma.j.issn.0254-6450.2018.06.019 |
|
[10] |
Protasov AD, Zhestkov AV, Kostinov MP, et al. Analysis of the effectiveness and long-term results of formation of adaptive immunity in the use of various medications and vaccination schemes against pneumococcal infection in patients with chronic obstructive pulmonary disease[J]. Ter Arkh, 2017, 89(12.Vyp.2): 165-174. DOI:10.17116/terarkh20178912165-174 |
|
[11] |
Walters JAE, Tang JNQ, Poole P, et al. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2017, 1(1): CD001390. DOI:10.1002/14651858.CD001390.pub4 |
|
[12] |
邱英鹏, 赵琨, 李雪, 等. 中国农村老年慢性阻塞性肺病患者接种23价肺炎多糖疫苗的卫生经济学评价[J]. 中华预防医学杂志, 2016, 50(12): 1074-1078. Qiu YP, Zhao K, Li X, et al. Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China[J]. Chin J Prev Med, 2016, 50(12): 1074-1078. DOI:10.3760/cma.j.issn.0253-9624.2016.12.010 |
|
[13] |
刘磊, 刘彬, 朱莉莉, 等. 慢性阻塞性肺疾病患者接种流感疫苗的获益研究[J]. 山西医药杂志, 2018, 47(23): 2775-2777. Liu L, Liu B, Zhu LL, et al. Effect of influenza vaccine on patients with chronic obstructive pulmonary disease[J]. Shanxi Med J, 2018, 47(23): 2775-2777. DOI:10.3969/j.issn.0253-9926.2018.23.001 |
|
[14] |
Li Y, Ma Y, An ZJ, et al. Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease[J]. Hum Vaccin Immunother, 2021, 17(9): 3131-3136. DOI:10.1080/21645515.2021.1911515 |
|
[15] |
Staples KJ, Williams NP, Bonduelle O, et al. Acquired immune responses to the seasonal trivalent influenza vaccination in COPD[J]. Clin Exp Immunol, 2019, 198(1): 71-82. DOI:10.1111/cei.13336 |
|
[16] |
Chuaychoo B, Kositanont U, Rittayamai N, et al. The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A (H1N1) pdm09 in COPD patients soon after a pandemic[J]. Hum Vaccin Immunother, 2016, 12(7): 1728-1737. DOI:10.1080/21645515.2016.1149276 |
|
[17] |
Wongsurakiat P, Maranetra KN, Wasi C, et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: A randomized controlled study[J]. Chest, 2004, 125(6): 2011-2020. DOI:10.1378/chest.125.6.2011 |
|
[18] |
Garrastazu R, García-Rivero JL, Ruiz M, et al. Prevalence of influenza vaccination in chronic obstructive pulmonary disease patients and impact on the risk of severe exacerbations[J]. Arch Bronconeumol, 2016, 52(2): 88-95. DOI:10.1016/j.arbres.2015.09.001 |
|
[19] |
Gershon AS, Chung H, Porter J, et al. Influenza vaccine effectiveness in preventing hospitalizations in older patients with chronic obstructive pulmonary disease[J]. J Infect Dis, 2020, 221(1): 42-52. DOI:10.1093/infdis/jiz419 |
|
[20] |
Mulpuru S, Li L, Ye LY, et al. Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD[J]. Chest, 2019, 155(1): 69-78. DOI:10.1016/j.chest.2018.10.044 |
|
[21] |
Bao WY, Li Y, Wang T, et al. Effects of influenza vaccination on clinical outcomes of chronic obstructive pulmonary disease: A systematic review and meta-analysis[J]. Ageing Res Rev, 2021, 68: 101337. DOI:10.1016/j.arr.2021.101337 |
|
[22] |
Huang CL, Nguyen PA, Kuo PL, et al. Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly[J]. Comput Methods Programs Biomed, 2013, 111(2): 507-511. DOI:10.1016/j.cmpb.2013.05.006 |
|
[23] |
Sung LC, Chen CI, Fang YA, et al. Influenza vaccination reduces hospitalization for acute coronary syndrome in elderly patients with chronic obstructive pulmonary disease: a population-based cohort study[J]. Vaccine, 2014, 32(30): 3843-3849. DOI:10.1016/j.vaccine.2014.04.064 |
|
[24] |
Chen KY, Wu SM, Liu JC, et al. Effect of annual influenza vaccination on reducing lung cancer in patients with chronic obstructive pulmonary disease from a population- based cohort study[J]. Medicine (Baltimore), 2019, 98(47): e18035. DOI:10.1097/MD.0000000000018035 |
|
[25] |
Luo CS, Chi CC, Fang YA, et al. Influenza vaccination reduces dementia in patients with chronic obstructive pulmonary disease: a nationwide cohort study[J]. J Investig Med, 2020, 68(4): 838-845. DOI:10.1136/jim-2019-001155 |
|
[26] |
Huang HH, Chen SJ, Chao TF, et al. Influenza vaccination and risk of respiratory failure in patients with chronic obstructive pulmonary disease: A nationwide population- based case-cohort study[J]. J Microbiol Immunol Infect, 2019, 52(1): 22-29. DOI:10.1016/j.jmii.2017.08.014 |
|
[27] |
Chang HC, Liu SF, Li YC, et al. The effectiveness of influenza vaccination on chronic obstructive pulmonary disease with different severities of airflow obstruction[J]. Biomedicines, 2021, 9(9): 1175. DOI:10.3390/biomedicines9091175 |
|
[28] |
Young-Xu Y, Smith J, Nealon J, et al. Influenza vaccine in chronic obstructive pulmonary disease among elderly male veterans[J]. PLoS One, 2022, 17(1): e0262072. DOI:10.1371/journal.pone.0262072 |
|
[29] |
Furumoto A, Ohkusa Y, Chen M, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease[J]. Vaccine, 2008, 26(33): 4284-4289. DOI:10.1016/j.vaccine.2008.05.037 |
|
[30] |
Fekete M, Pako J, Nemeth AN, et al. Prevalence of influenza and pneumococcal vaccination in chronic obstructive pulmonary disease patients in association with the occurrence of acute exacerbations[J]. J Thorac Dis, 2020, 12(8): 4233-4242. DOI:10.21037/jtd-20-814 |
|
[31] | |
|
[32] |
Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2021-22 Influenza Season[J]. MMWR Recomm Rep, 2021, 70(5): 1-28. DOI:10.15585/mmwr.rr7005a1 |
|
[33] |
Matanock A, Lee G, Gierke R, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices[J]. MMWR Morb Mortal Wkly Rep, 2019, 68(46): 1069-1075. DOI:10.15585/mmwr.mm6846a5 |
|
[34] | |
|
[35] | |
|
[36] |
World Health Organization. Vaccines against influenza WHO position paper - November 2012[J]. Wkly Epidemiol Rec, 2012, 87(47): 461-476. |
|
[37] |
Alcusky MJ, Pawasauskas J. Adherence to guidelines for Hepatitis B, pneumococcal, and influenza vaccination in patients with diabetes[J]. Clin Diabetes, 2015, 33(3): 116-122. DOI:10.2337/diaclin.33.3.116 |
|
[38] |
Song Z, Liu XF, Xiang PC, et al. The current status of vaccine uptake and the impact of COVID-19 on intention to vaccination in patients with COPD in Beijing[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16: 3337-3346. DOI:10.2147/COPD.S340730 |
|
[39] |
樊静, 丛舒, 王宁, 等. 2014-2015年中国40岁及以上慢性阻塞性肺疾病患者肺炎疫苗接种状况[J]. 中华流行病学杂志, 2020, 41(7): 1028-1033. Fan J, Cong S, Wang N, et al. Pneumococcal vaccination rate in chronic obstructive pulmonary disease patients aged 40 years or older in China, 2014-2015[J]. Chin J Epidemiol, 2020, 41(7): 1028-1033. DOI:10.3760/cma.j.cn112338-20200124-00056 |
|